

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**NOVO GROUP LTD.**  
**新源控股有限公司\***  
*(Incorporated in Singapore with limited liability)*  
*(Company Registration No. 198902648H)*  
**Hong Kong Stock Code: 1048**  
**Singapore Stock Code: MR8**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This overseas regulatory announcement is a reproduction of the announcement made by Novo Group Ltd. (the “**Company**”) for compliance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Please refer to the attached announcement on the next page issued on the Singapore Exchange Securities Trading Limited on 23 December 2014.

By order of the Board  
**Novo Group Ltd.**  
**Yu Wing Keung, Dicky**  
*Executive Chairman*

Hong Kong, 23 December 2014

*As at the date of this announcement, the Board comprises three executive Directors, being Mr. Yu Wing Keung, Dicky, Mr. Chow Kin Wa, Mr. Chow Kin San and three independent non-executive Directors, being Mr. Tang Chi Loong, Mr. Foo Teck Leong and Mr. Tse To Chung, Lawrence.*

\* *For identification purpose only*

## **NOVO GROUP LTD.**

Registration No. 198902648H

Incorporated in the Republic of Singapore

---

### **FURTHER CAPITAL INJECTION TO NOVOWELL ETP LIMITED**

---

*Unless otherwise defined, all terms used or referred to in this announcement have the meanings assigned to them in the Company's announcements dated 15 March 2011, 28 June 2011 and 15 October 2012 and the circular to its shareholders dated 2 September 2011.*

The board (the "Board") of directors (the "Directors") of Novo Group Ltd. (the "Company" or together with its subsidiaries, the "Group") wishes to announce that, Novo ETP and Tong Chang have agreed to further contribute to the registered share capital of Novowell ETP, being a 95% owned subsidiary established in the People's Republic of China to undertake manufacturing and marketing of ETP products, on a pro-rata basis of US\$2,926,000 and US\$154,000, respectively, in order to meet the future funding requirements (the "3<sup>rd</sup> Capital Injection"). Thereafter, the total registered capital of Novowell ETP shall increase from US\$17,500,000 to US\$20,580,000 and the Group's equity interest in Novowell ETP shall remain at 95% upon completion of the 3<sup>rd</sup> Capital Injection.

The total registered capital of Novowell ETP was US\$17,500,000, which had been fully paid up, prior to the 3<sup>rd</sup> Capital Injection.

The Group's share of the 3<sup>rd</sup> Capital Injection of US\$2,926,000 be funded through internal resources and is not expected to have any significant impact on the financial position of the Company for the current financial year ending 30 April 2015.

Save as the above disclosure, none of the Directors and/or controlling shareholders of the Company has any interest, direct or indirect (other than through their shareholdings in the Company), in the said transaction.

#### **BY ORDER OF THE BOARD**

Yu Wing Keung, Dicky  
Executive Chairman  
23 December 2014